Abingworth sees buoyant times ahead for life sciences

London-based investor, which focuses on U.S. and European healthcare deals, raises $376 million for sixth Bioventures fund

1 April 2014•2 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.